For Specific IgE and IgG Analysis

The ImmunoCAP platform is used to measure total or specific IgG and IgE antibodies in samples. BioAgilytix offers ImmunoCAP assay development and testing services at our laboratory in Hamburg, Germany, to deliver reproducible results.  

immuno cell rendering

BioAgilytix’s ImmunoCAP platform expertise  

Our scientific team has proven their ability to efficiently, consistently perform assays using ImmunoCAP, and to develop robust assays used to produce timely results. We have vast experience leveraging this platform to develop custom assays for determining drug-specific IgE and IgG responses for understanding immunogenicity. 

researcher looking at vial
Key ImmunoCAP Benefits:

Automated processing and reproducible results 

The key advantages of the ImmunoCAP platform include its ability to enable high productivity, high sensitivity, and high drug tolerance. Using automated processing, the platform can also provide standardized and reproducible results. 

Designed as sandwich assays, the solid phase of ImmunoCAP ensures binding of all relevant antibodies. This is achieved through an extreme binding capacity on the ImmunoCAP surface. We use ImmunoCAP assays to deliver accurate and reproducible results with increased efficiency and shortened turnaround times, achieved with the platform’s high-throughput automation capabilities. 

Benefits of the ImmunoCAP platform include: 

  • High sensitivity 
  • High specificity 
  • Standardized, reproducible results 
  • Automated processing 
Ideal ImmunoCAP Applications:

For IgE-mediated hyperreactivity analysis 

ImmunoCAP offers very sensitive IgE detection in the low ng- or pg range with high precision. It can be used to determine IgE mediated immunogenicity and enables IgE antibody detection at an early stage, indicating sensitization—even before clinical symptoms have developed. 

BioAgilytix leverages the use of the ImmunoCAP platform to measure anti-drug IgE antibodies in samples for immunogenicity studies.  


How the ImmunoCAP platform works  

The technology used in the ImmunoCAP platform enables a high binding capacity per mg cellulose in combination with an optimal amount of cellulose in each solid phase. This ensures binding of all relevant antibodies, regardless of antibody affinity, still giving low non-specific binding. The ImmunoCAP solid phase consists of a cellulose derivative enclosed in a capsule. The hydrophilic, highly branched polymer provides an ideal microenvironment for binding proteins. 

The test is designed as a sandwich immunoassay. Biotinylated drug, bound to streptavidin-coated solid phase, reacts with the drug-specific IgE in the patient serum sample. After washing, enzyme-labeled antibodies against IgE or IgG are added to form a complex. After incubation, unbound enzyme labeled antibody is washed away, and the bound complex is then incubated with a developing agent. After stopping the reaction, the fluorescence of the eluate is measured. The fluorescence is directly proportional to the concentration of IgE or IgG in the serum sample.


Platform spotlight: ImmunoCAP to support diagnosis of allergic reactions against biologics